Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Retained Earnings (2023 - 2025)

Historic Retained Earnings for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $3.7 million.

  • Zhengye Biotechnology Holding's Retained Earnings changed N/A to $3.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $3.7 million, marking a year-over-year change of. This contributed to the annual value of $6.7 million for FY2024, which is 2338.78% up from last year.
  • Per Zhengye Biotechnology Holding's latest filing, its Retained Earnings stood at $3.7 million for Q2 2025.
  • Zhengye Biotechnology Holding's Retained Earnings' 5-year high stood at $6.7 million during Q4 2024, with a 5-year trough of $3.7 million in Q2 2025.
  • Its 3-year average for Retained Earnings is $5.2 million, with a median of $5.3 million in 2023.
  • Data for Zhengye Biotechnology Holding's Retained Earnings shows a peak YoY increase of 2575.19% (in 2024) and a maximum YoY decrease of 2575.19% (in 2024) over the last 5 years.
  • Zhengye Biotechnology Holding's Retained Earnings (Quarter) stood at $5.3 million in 2023, then increased by 25.75% to $6.7 million in 2024, then plummeted by 45.38% to $3.7 million in 2025.
  • Its last three reported values are $3.7 million in Q2 2025, $6.7 million for Q4 2024, and $5.3 million during Q4 2023.